Subscribe
shutterstock_728430565_casimiropt
casimiropt / Shutterstock.com
15 May 2019Americas

Clean sweep for AbbVie in Humira litigation

Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira (adalimumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers